The poster, titled 'Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology,' was presented by Dr.
In the largest retrospective, single-institution, real-world study of CNSide, samples were analyzed from all neuro-oncology patients with suspected LM who underwent lumbar puncture from
'The findings from this largest-ever, retrospective study with CNSide are highly encouraging, with the authors noting that all cytology positive and equivocal cases of LM were detected by CNSide. We are delighted that new, third-party data highlighting CNSide were shared at one of the most prestigious and largest oncology conference of the year,' said
'We recently began patient enrollment in our FORESEE clinical trial with the goal of generating further evidence of the clinical utility of CNSide in detecting cancers that have metastasized to the central nervous system,' he added. 'The findings of this trial will be important in our efforts to expand the commercialization of this important test to detect the presence of tumor, as well as to guide and monitor therapy for these terminally ill patients.'
About the FORESEE Clinical Trial
In
Standard-of-care methods to diagnose or assess the treatment response of LM (i.e., clinical evaluation, MRI and cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. CNSide is a Laboratory Developed Test (LDT) that is used commercially at the physician's discretion, with samples processed in
About CNSide
Using our proprietary CNSide assay to analyze and interrogate CSF-TCs and cfDNA for certain biomarkers, physicians can be better informed about the actionable molecular information associated with a patient's metastatic cancer and develop a personalized cancer treatment plan. Through CNSide,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like 'may,' 'will,' 'should,' 'could,' 'expect,' 'anticipate,' 'estimate,' 'believe,' 'intend,' or 'project' or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to close the offering, the proceeds from the offering, and our intended use of the proceeds from the offering, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors, including market conditions, and the risks set forth in our
Contact:
Email: Jcain@lhai.com
Tel: 310-691-7100
(C) 2023 Electronic News Publishing, source